GCP
UBX

GSA Capital Partners’s Unity Biotechnology UBX Stock Holding History

GSA Capital Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-63,994
Closed -$361K – 1874
2022
Q2 		$361K Sell
63,994
-8,426
-12% -$70.3K 0.05% 708
2022
Q1 		$811K Buy
72,420
+2,808
+4% +$31.5K 0.11% 268
2021
Q4 		$1.02M Buy
69,612
+22,875
+49% +$500K 0.13% 196
2021
Q3 		$1.4M Buy
46,737
+26,149
+127% +$923K 0.14% 154
2021
Q2 		$955K Buy
+20,588
New +$991K 0.11% 276
2020
Q4 		– Sell
-3,044
Closed -$105K – 1612
2020
Q3 		$105K Buy
+3,044
New +$193K 0.02% 1130

Other funds holding UBX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
ACM
Altium Capital Management New York $42M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return